Impaired surface antigen presentation in tumors: Implications for T cell-based immunotherapy

Seminars in Cancer Biology

Volumn 12, Issue 1, 2002, Pages 15-24

  Ruiz Cabello, Francisco ^a   Cabrera, Teresa ^a   Lopez Nevot, Miguel Angel ^a   Garrido, Federico ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Antigen presentation; HLA class I molecules; Immunotherapy; Peptide antigens; T lymphocytes; Tumor escape

Indexed keywords

CD8 ANTIGEN; HLA ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CHROMOSOME 6; HETEROZYGOSITY LOSS; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; NONHUMAN; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNOLOGY;

EID: 0036155882     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0406     Document Type: Article

References (62)

1. Demostration of resistence against methyl-cholanthrene-induced sarcomas in the primary autochthonous host
2. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
3. Immunologic and therapeutic evaluation of a synthetic paptide vaccine for the treatment of patients with metastatic melanoma
4. Natural history of HLA expression during tumour development
5. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
6. Generation, translocation, and presentation of MHC class I-restricted peptides
7. Class I MHC molecules: Assembly and antigen presentation
8. The nature of the MHC class I peptide loading complex
9. Species-specific differences in chaperone interaction of human and mouse histocompatibility complex class I molecules
10. Molecular chaperones in antigen presentation
11. Viral subversion of the immune system
12. Immune surveillance against a solid tumor fails because of immunological ignorance
13. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
14. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors
15. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas
16. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor escape
17. The host-tumor immune conflict from immunosuppression to resistance and destruction
18. Immune evasion of tumor cells using membrane-bound complement regulatory proteins
19. Immunoselection by T lymphocytes generates repeated MHC class I- deficient metastatic tumor variants
20. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic immunocompetent mice
21. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection
22. The HLA crossroad in tumor immunology
23. Antigen-processing machinery breakdown and tumor growth
24. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression
25. Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas
26. A new beta 2 microglobulin mutation found in a melanoma tumor cell line
27. 2 microglobulin gene mutation is not a common mechanism of HLA class I down-regulation in human tumours
28. 2-microglobulin gene result in lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides
29. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif
30. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions
31. Analysis of expression of the melanoma associated antigens MART-1 and gp 100 in metastatic melanoma cell lines and in situ lesions
32. NK cell receptors
33. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis
34. Can the HLA phenotype be used as a prognostic factor in breast carcinomas?
35. Altered expression of HLA class I antigens in breast cancer: Association with prognosis
36. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA
37. Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression
38. Tumor escape from immune recognition: Loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6
39. The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules
40. Regulation of MHC class I and II gene transcription: Differences and similarities
41. DNA binding of regulatory factors interacting with MHC class I gene enhancer correlates with MHC class I transcriptional level in class I defective cell lines
42. N-myc supresses major histocomaptibility complex class I gene expression through dow-regulation of the p50 subunit of NFκB
43. Overexpression of Cdx1 and Cdx2 homeogenes enhances expression of the HLA-I in HT-29 cells
44. Integration of high-risk human papillomavirus DNA is linked to the down-regulation of class I human leukocyte antigens by steroid hormones in cervical tumor cells
45. Methylation status and trasncriptional expression of the MHC class I loci in human trophoblast cells from term placenta
46. HLA class I gene expression on human primary tumours and autologous metastases: Demostration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas
47. Reexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-Aza-2′-deoxycytidine treatment
48. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines
49. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line
50. Locus-specific transcriptional control of HLA genes
51. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: Comparison of HLA genotype and surface expression on colorectal tumor cell lines
52. Multiple mechanisms underlie HLA dysregulation in cervical cancer
53. A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts both in tumoral and normal cells
54. Multiple genetic alterations cause frequent and heterogenoeus human histocompatibility leukocyte antigen class I loss in cervical cancer
55. The selective downregulation of class I major-histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells
56. Molecular strategies to define HLA haplotype loss in microdissected tumor cells
57. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors
58. Criteria to define HLA haplotype loss in human solid tumors
59. C-myc downregulates class I HLA expression in human melanomas
60. Identification of CCAAT displacement protein CDP/cut as a locus-specific repressor of major histocomaptibility complex gene expression in human tumor cells
61. Selective histocompatibility leukocyte antigen HLA-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells
62. HLA and cancer